Inhibikase Therapeutics, Inc. (IKT)

Over the past six months, Inhibikase Therapeutics' stock has been influenced by analyst ratings and price targets, including a "Buy" recommendation from B of A Securities in January 2026. Public and private offerings, such as the November 2025 public offering of common stock and pre-funded warrants, and the October 2024 pricing of a $110 million private placement to advance IkT-001Pro, have also played a role. Drug development updates, including advancing IKT-001 to a global Phase 3 study in pulmonary arterial hypertension, and the decision to halt further development of risvodetinib (IkT-148009) due to adverse events, have impacted the stock. As of February 6, 2026, IKT shares have decreased by 17.1% since the start of the year, and over the past year, the stock has experienced a decline of 33.05% as of February 4, 2026. The 52-week trading range for IKT has been between $1.33 and $3.32.

Information regarding specific demand seasonality for Inhibikase Therapeutics, Inc. products and services is not readily available in the provided search results. Access to this detailed data typically requires a subscription or account.

Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company focused on developing small-molecule kinase inhibitor therapeutics for neurodegenerative and infectious diseases affecting the nervous system, as well as cardiopulmonary diseases. The company operates within the Healthcare sector, specifically in the Biotechnology industry, and utilizes a proprietary drug development platform to create innovative therapies. Its major product candidates include IkT-148009 (risvodetinib), a non-receptor Abelson tyrosine kinase inhibitor in Phase 2a clinical trials for Parkinson's disease and related disorders, and IKT-001Pro, a prodrug of imatinib mesylate, being developed for pulmonary arterial hypertension (PAH) and stable phase chronic myelogenous leukemia (CML). The company is advancing IKT-001 towards a late-stage clinical trial in PAH, with a Phase 2b study (IMPROVE-PAH) expected to initiate in the second half of 2025.

Inhibikase Therapeutics, Inc. is based in Atlanta, Georgia, United States. The company has research and development collaborations with several academic institutions, including Johns Hopkins University, Arizona State University, and Michigan State University. Additionally, it has a collaborative research and development agreement with Sphaera Pharma Pte. Ltd.

In the past year, Inhibikase Therapeutics has experienced a mixed brand reputation. The company has received a consensus "Buy" rating from analysts, with some even giving a "Strong Buy" rating, noting promising results with risvodetinib. Advancements in the manufacturing process and the FDA's endorsement of its Phase 2 trial design for IkT-001 Pro have also strengthened its growth potential. However, the decision to halt further development of risvodetinib due to reported adverse events in a Phase 2 trial has negatively impacted its reputation and led to a stock rating downgrade.

Inhibikase Therapeutics, Inc. has a significant number of institutional owners and shareholders. As of February 4, 2026, 114 institutional owners hold a total of 58,274,830 shares. Major institutional shareholders include Sands Capital Ventures, LLC, Soleus Capital Management, L.P., Fairmount Funds Management LLC, Perceptive Advisors Llc, Commodore Capital Lp, ADAR1 Capital Management, LLC, Vanguard Group Inc, BlackRock, Inc., and Blackstone Group Inc. Individual investors also control a substantial portion of the company, with their ownership suggesting that key decisions are influenced by shareholders from the larger public.